Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Gene therapy appears effective in bladder cancer patients with few options
Key clinical point: An intravesical gene therapy, nadofaragene firadenovec, is effective in patients with non–muscle invasive bladder cancer that does not respond to Bacillus Calmette-Guerin.
Major finding: At 3 months, the rate of high-grade recurrence-free survival was 59.6% overall, 53.4% for patients with carcinoma in situ, and 72.9% for patients with high-grade Ta or T1 papillary disease.
Study details: A single-arm, phase 3 trial of 157 patients with non–muscle invasive bladder cancer that did not respond to Bacillus Calmette-Guerin (107 with carcinoma in situ, 50 with papillary disease only).
Disclosures: The trial was funded by FKD Therapies Oy. Dr. Boorjian disclosed relationships with Ferring and Sanofi.
Boorjian SA et al. GUCS 2020, Abstract 442.